01/11/23 8:00 AMNasdaq : CLNN Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23 Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced that it will participate in Renmark Financial CommunicationsRHEA-AIneutral
12/27/22 4:01 PMNasdaq : CLNN clinical trialcovid-19Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAgClene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) andRHEA-AIneutral
12/12/22 8:00 AMNasdaq : CLNN Clene Announces Closing of $5 Million Debt Facility from the State of MarylandClene Inc. (Nasdaq: CLNN) (along with its subsidiaries “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., aRHEA-AIvery positive
11/28/22 8:00 AMNasdaq : CLNN VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying TherapiesCNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapies (DMTs) No approved MS DMTs have shownRHEA-AIneutral
11/07/22 8:00 AMNasdaq : CLNN earningsClene Reports Third Quarter 2022 Financial Results and Recent Operating HighlightsSecondary survival endpoint for the CNM-Au8 ® 30 mg dose investigated in the Healey ALS Platform Trial demonstrated a >90% reduction in the risk of death or death equivalent (permanently assisted ventilation) and risk of death alone at 24 weeks. This survival benefit was consistent with priorRHEA-AIneutral
10/31/22 8:00 AMNasdaq : CLNN offeringClene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of MarylandClene Inc. (Nasdaq: CLNN) (along with its subsidiaries “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, todayRHEA-AIneutral
10/03/22 8:00 AMNasdaq : CLNN clinical trialClene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform TrialThe primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeks Prespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24RHEA-AIpositive
09/30/22 4:12 PMNasdaq : CLNN conferencesclinical trialClene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing theRHEA-AIneutral
09/21/22 7:00 AMNasdaq : CLNN Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific ConferenceTreatment with CNM-Au8 significantly improved long-term survival with approximately a 70% decreased risk of mortality vs. original placebo randomization Comparable survival benefits were also shown compared to ENCALS predicted median survival C NM-Au8 treatment was well-tolerated, and there were noRHEA-AIpositive
08/30/22 7:00 AMNasdaq : CLNN conferencesClene to Present at Upcoming September Investor ConferencesClene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, todayRHEA-AIneutral